H1N1 INFLUENZA: INFORMATION ON VIRUS MUTATION (Min. Health, edited)
[Source RTF Document: LINK. Edited. Warning: Google Machine Translation.]
Press No 547 - 30 November 2009 - Ministry of Labor, Health and Social Policies - PRESS OFFICE
H1N1 INFLUENZA: INFORMATION ON VIRUS MUTATION
About a week ago, the Norwegian health authorities have reported the identification of a single mutation haemagglutinin (viral protein surface) of the new flu virus H1N1, which is to change a single amino acid (a glycine instead of a aspartic acid) [D2226, NDM], in some patients with severe pneumonia. Sporadic cases of the same mutation have been reported, starting from April, in several countries around the world both in patients with severe pneumonia and patients with benign course of disease.
Following these reports, the National Institute of Health has reassessed the sequences of more than 100 strains identified by as many patients diagnosed in recent months in various Italian regions.
None of the other patients examined, including those with serious or life-threatening events, showed that mutation.
The Italian data confirmed that the mutation in question is not to be currently predominant in cases of serious or deadly new flu in addition, the same mutation has a sporadic and does not seem at this stage in the process of diffusion.
This mutation does not impair the effectiveness of the vaccine or treatment with antiviral drugs.
This resistance has been caused by prolonged treatment of a patient with severe pre-existing conditions and has remained isolated, not having responded to episodes of transmission of resistant strains.
--
------
[Source RTF Document: LINK. Edited. Warning: Google Machine Translation.]
Press No 547 - 30 November 2009 - Ministry of Labor, Health and Social Policies - PRESS OFFICE
H1N1 INFLUENZA: INFORMATION ON VIRUS MUTATION
About a week ago, the Norwegian health authorities have reported the identification of a single mutation haemagglutinin (viral protein surface) of the new flu virus H1N1, which is to change a single amino acid (a glycine instead of a aspartic acid) [D2226, NDM], in some patients with severe pneumonia. Sporadic cases of the same mutation have been reported, starting from April, in several countries around the world both in patients with severe pneumonia and patients with benign course of disease.
Following these reports, the National Institute of Health has reassessed the sequences of more than 100 strains identified by as many patients diagnosed in recent months in various Italian regions.
The mutation has been found so far in only one patient suffering from a severe form of pneumonia resolved following treatment with ECMO performed in intensive care.
The Italian data confirmed that the mutation in question is not to be currently predominant in cases of serious or deadly new flu in addition, the same mutation has a sporadic and does not seem at this stage in the process of diffusion.
This mutation does not impair the effectiveness of the vaccine or treatment with antiviral drugs.
In this connection it is recalled that, according to National Institute of Health, over 160 patients analyzed so far, has found a single case of resistance to oseltamivir.
--
------
Comment